Comparison of human and rat uterine leiomyomata: Identification of a dysregulated mammalian target of rapamycin pathway

Judy S. Crabtree, Scott A. Jelinsky, Heather A. Harris, Sung E. Choe, Monette M. Cotreau, Michelle L. Kimberland, Ewa Wilson, Kathryn A. Saraf, Wei Liu, Adrienne S. McCampbell, Bhuvanesh Dave, Russell R. Broaddus, Eugene L. Brown, Wenling Kao, Jerauld S. Skotnicki, Magid Abou-Gharbia, Richard C. Winneker, Cheryl L. Walker

Research output: Contribution to journalArticlepeer-review

68 Scopus citations

Abstract

Uterine leiomyomata, or fibroids, are benign tumors of the uterine myometrium that significantly affect up to 30% of reproductive-age women. Despite being the primary cause of hysterectomy in the United States, accounting for up to 200,000 procedures annually, the etiology of leiomyoma remains largely unknown. As a basis for understanding leiomyoma pathogenesis and identifying targets for pharmacotherapy,we conducted transcriptional profiling of leiomyoma and unaffected myometrium from humans and Eker rats, the best characterized preclinical model of leiomyomata. A global comparison of mRNA from leiomyoma versus myometrium in human and rat identified a highly significant overlap of dysregulated gene expression in leiomyomata. An unbiased pathway analysis using a method of gene-set enrichment based on the sigPathway algorithm detected the mammalian target of rapamycin (mTOR) pathway as one of the most highly up-regulated pathways in both human and rat tumors. To validate this pathway as a therapeutic target for uterine leiomyomata, preclinical studies were conducted in Eker rats. These rats develop uterine leiomyomata as a consequence of loss of Tsc2 function and up-regulation of mTOR signaling. Inhibition of mTOR in female Eker rats with the rapamycin analogue WAY-129327 for 2 weeks decreased mTOR signaling and cell proliferation in tumors, and treatment for 4 months significantly decreased tumor incidence, multiplicity, and size. These results identify dysregulated mTOR signaling as a component of leiomyoma etiology across species and directly show the dependence of uterine leiomyomata with activated mTOR on this signaling pathway for growth.

Original languageEnglish (US)
Pages (from-to)6171-6178
Number of pages8
JournalCancer research
Volume69
Issue number15
DOIs
StatePublished - Aug 1 2009

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Comparison of human and rat uterine leiomyomata: Identification of a dysregulated mammalian target of rapamycin pathway'. Together they form a unique fingerprint.

Cite this